Latest Headlines

Latest Headlines

Bristol-Myers taps Oncodesign to serve up targets for new cancer drugs

Bristol-Myers Squibb recruited French biotech Oncodesign to help it find new ways of attacking tumors, signing an early-stage agreement in hopes of spotlighting some promising projects.

UPDATED: AstraZeneca looks to bag an Imbruvica rival as it hunts Acerta buyout

Four days after Acerta Pharma quietly posted some promising early-stage data on its Bruton's tyrosine kinase inhibitor acalabrutinib, AstraZeneca has popped up as a potential buyer. Dow Jones reported Friday afternoon that the pharma giant is well down the road in talks to buy Acerta for more than $5 billion, potentially landing another cancer drug for its growing oncology pipeline.

Bayer looks to bone up in oncology after slipping behind rivals

German pharma giant Bayer is playing catch-up in the field of cancer treatments, expanding its efforts in hopes of cutting in on the burgeoning oncology market.

ASH scorecard: AbbVie rides high, GBT slips and Celgene settles in

AbbVie, questing to justify its colossal buyout of Pharmacyclics, came away among the winners of the weekend's American Society of Hematology meeting, while the recently IPO'd Global Blood Therapeutics ran into mixed results with its sickle cell therapy and Celgene doubled down on immuno-oncology.

Ex-GSK cancer chief Paoletti scores $29M war chest for multiple myeloma startup Kesios

When Paolo Paoletti joined GlaxoSmithKline in 2011 to build an oncology group, the number of cancer specialists on staff ranged in the dozens. By the time GSK decided to scrap the organization in a swap with Novartis, he had recruited 2,000 staffers around the world working on a full pipeline of therapies.

Sanofi inks a $1.5B deal to join BioNTech's growing list of oncology partners

Sanofi is pairing up with Germany's BioNTech in a collaboration potentially worth $1.5 billion, licensing some early-stage cancer immunotherapies that use messenger RNA to target tumors.

Merck KGaA inks cancer metabolism drug discovery alliance with Selvita

Merck KGaA has teamed up with Selvita to discover small molecule drugs against multiple oncology indications. The alliance builds on an earlier two-year research collaboration into the discovery of enzyme inhibitors to regulate metabolic processes in cancer cells.

GlaxoSmithKline's cardio R&D group records another big PhIII flop

More than a year after its second big Phase III program for darapladib also turned out to be a bust, GlaxoSmithKline is reporting today that losmapimod--cited by CEO Andrew Witty as a top late-stage program--failed to measure up in the first leg of a clinical marathon. And it's not planning to fund step two.

Merck, Incyte eye a winning cancer combo with widened collaboration

Partners Merck and Incyte are broadening their oncology alliance, moving into Phase III with a pair of treatments that use the body's natural defenses to fight cancer.

Amgen vet reveals stealth startup Flexus backed by $38M from Kleiner Perkins, Celgene

After shunning public attention for more than a year, cancer immunotherapy startup Flexus Biosciences is ready for the limelight now that it is headed toward the clinic, has banked its first two venture rounds totaling $38 million and boasts impressive management, board and advisory rosters.